Life Without Any Curement
Enjoy Good Life with Maintaining Your Health and Beauty
Further research is promising cancer treatment
A protein that functions as a cancer drug for leadership in animal experiments has been developed by an international team that includes several researchers from the University of Western Australia.
The natural protein is known to play an important role in promoting cell death (for example in mammary cells after the young are weaned), prevention of cell proliferation, promoting cell differentiation, and in this new discovery, by blocking the formation of blood vessels.
The trial results, published in the American Journal of Pathology showed that the protein – related protein secreted curly 4 (sFRP4) – inhibits tumors in the same degree as a very successful antibody, Avastin ®.
Winthrop Professor Arun Dharmaraj UWA School of Anatomy and Human Biology and UWA, said Anna University (AU), Chennai, India, holders of patents on the use of sFRP4 as angiogenesis inhibitor and are eager to find a trading partner for project.
Incoming search terms for the article:
Powered By Pligg human biology (4),Powered By Pligg types of biotechnology (3),whey european cancer treatment (1),WHAT KIND OF CANCER DOES DORIS DALTON HAVE (1),simon handford (1),role of biotechnology in cancer (1),PROF Dharmaraj UWA (1),Prof Dharmaraj Biotechnology Chennai (1),angiogenesis inhibitor sFRP4 (1),Powered By Pligg biotechnology industry (1),Powered By Pligg biology degree (1),interesting results further research (1),Dr Dharmaraj uwa (1),Dr Dharmaraj cancer australia (1),doris dalton cancer (1),young vagina hair (1)
The inactivation of genes with the growth of cancer near Skp2
A better understanding of Skp2 gene and its relation to cellular senescence can lead to the development of new agents that can suppress tumor growth in certain types of cancer, researchers at the University of Texas, MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center report in the journal Nature. Journal Skp2 is involved in promoting cell cycle regulation, cell proliferation, cell growth and tumor formation, and is overexpressed in a variety of human cancers, according to lead author Hui-Kuan Lin, Ph.D., professor MD Anderson Cancer assistant molecular and cell biology.
Lin and colleagues found that inactivation oncogenes are overexpressed Skp2 after strangling cancer growth by inducing senescence – the irreversible loss of the ability of a cell to divide and grow. Harnessing the power of cellular senescence to push rapidly dividing cells in a dormant state could provide an alternative means of prevention or control of the common malignant tumors such as prostate cancer.
Incoming search terms for the article:
Powered By Pligg biology cell (5),Powered By Pligg biology sites (5),Powered By Pligg laboratory technician (4),Powered By Pligg current biology (4),Powered By Pligg bowel injury (3),Powered By Pligg recent biology articles (3),senescence pten (1),Powered By Pligg texas secretary of state (1),MD ANderson cancer center malignant peritoneal fluid (1),skp2 (1)
Colon cancer treatment in elderly patients often less aggressive than recommended
The new findings of a major initiative on the quality of cancer care in the United States show that patients with a common type of cancer of the colon, particularly older patients often do not receive aggressive chemotherapy showing research is associated with improved survival.
Led by researchers at UCLA and the Rand Corporation, a nonprofit research, the study is among the first to determine how the results of specialized research tests are applied in various practices in the community, where a greater variety of patients are treated. The findings appear in the March 17 edition of the Journal of American Medical Association, dedicated to the development of cancer care.
The study indicates that older patients, and to some extent young people often do not receive recommended care based on the results of clinical trials. The results show that patients with stage 3 colon cancer – time when the cancer has spread to lymph nodes – have less recurrence of cancer and improved survival if they receive chemotherapy to “lock” in a state free of cancer after surgical removal of cancer. Studies also show that adjuvant chemotherapy improves the outlook for patients in all age groups.
Incoming search terms for the article:
vaginapicture (30),treatment of colon cancer in the elderly (2),treatment for colon cancer in the elderly (2),studies related to why chemotherapy toxicity is more common in elderly colon cancer patients than young (2),is colon cancer aggressive (2),treatment for elderly diagnosed with colon cancer (1),studies related to effectivness of surgery and chemotherapy for elderly colon cancer (1),Powered By Pligg ucla internal medicine (1),colon cancer treatment for elderly patients (1),colon cancer in the elderly less aggressive than the young (1),chemotherapy toxicity of elderly cancer patients (1),agressive colon cancer in the elderly/treatment (1),aggressive chemotherapy follow colorectal cancer (1)
Clinical and patient preferences for information exchange shock prior to transplantation
Most donors and kidney recipients for the exchange of personal health information that may influence success before agreeing on an organ transplant from a living donor, while health professionals are more reluctant according to a study published in an upcoming issue of the Journal of the American Society of Clinical Nephrology (CJASN). The results suggest that physicians should consider supporting and facilitating the exchange of information prior to transplantation.
The living kidney donation is a complex decision with multiple medical, legal and ethical. In many situations it may be difficult to know what personal health information is important to share and what information should remain confidential. For example, knowing that the donor has high blood pressure can affect the willingness of a recipient to accept the gift, or a potential beneficiary who is HIV positive may fear that. Information may change the willingness of donors to make a donation.
Through the orientation of cells can prevent a relapse of leukeamia
About 40 percent of children and up to 70 percent of adults in remission from Acute Myeloid Leukemia (AML) will have a relapse. In recent years, doctors have come to believe that this is due to leukemia stem cells, constantly replicating cancer cells that produce immature blood cells characteristic of leukemia and are resistant to traditional cancer treatments. Now, researchers at Children’s Hospital Boston have discovered a possible way to kill these cells and prevent the release of a relapse.The study, published online March 26 in the journal Science, shows that leukemic stem cells can not thrive without a particular cellular pathway, known as the Wnt / beta-catenin, suggesting that targeting this pathway may inhibit the growth and development of AML.
“The greatest potential of this study is the suppression of relapse of leukemia with a drug that inhibits beta-catenin,” says Scott Armstrong, MD, PhD, Division of Children pediatric hematology / oncology and lead author of the study.
Incoming search terms for the article:
Genetic testing can be targeted cancer therapy
Scientists have found a way to identify patients with breast cancer are likely to respond to a type of chemotherapy. The new test also predict that is unlikely to see the benefit of treatment and help save them from unnecessary side effects.
The results – presented by researchers at the European Cancer Conference in Spain – that doctors should be able to tailor treatment to patients who will benefit and avoid the administration of toxic drugs for those not rescued.
In conducting a review of four large studies of breast cancer, researchers have discovered an abnormality on chromosome 17, called CEP17 is an indicator of “very important” that the tumor response to chemotherapy with anthracyclines call.
New gateway to treat leukaemia and other cancers
Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The results of the University of Montreal, Maisonneuve-Rosemont Hospital and Laval University may change doctors treat cancer patients.
“We found a door, which is present in all human beings, which enables anti-cancer agents such as bleomycin to enter the body so they can reach and attack the leukemia cells,” says lead author Dindial Ramotar , a professor at the Faculty of Medicine of the University of Montreal and a research affiliate at the Maisonneuve-Rosemont.
Dr. Ramotar has begun to test his theory ten years ago with the help of yeast, which is remarkably similar to human cells. “Our discovery has increased in this model system for human cells and will soon come to bed due to the therapy of translation, he said.” We are about to test patients. ”
Well tolerated specific nodal radiotherapy after surgery in women with breast cancer in early stage
In patients with early breast cancer, giving radiotherapy to the lymph nodes behind the breastbone and above the clavicle is well tolerated after a mastectomy or a lumpectomy, a radiation oncologist to delegates at the Seventh European Cancer Conference Breast (EBCC7) Saturday, March 27. Women at high risk of developing breast cancer likely benefit from additional nodal radiation therapy, Dr. Philip Poortmans, Dr. Bernard Verbeet Instituut Tilburg, the Netherlands, and member of the European Organization for Research and Treatment of Cancer (EORTC ) Radiation Oncology Group, said. The first results of the 4004-patient multicenter study carried out by radiation therapy and breast cancer groups EORTC (46 institutions in 13 countries) shows no evidence of increased toxicity in the heart of three years of follow-up among patients receiving additional lymph node radiotherapy.
Patients were followed for many years to see if the specific radiation of lymph nodes can cause long term damage of the heart or lungs, the side effects associated with radiation therapy for breast cancer.
Incoming search terms for the article:
Breast cancer with BRCA mutations four times more likely to have a contralateral breast cancer
Women with breast cancer before the age of 55 who have a mutation in the genes inherited breast cancer susceptibility BRCA1 or BRCA2 genes are four times more likely to develop breast cancer in the forehead, or contralateral their initial tumor compared to breast cancer patients without these genetic defects. These results, Fred Hutchinson Cancer Research Center Breast Cancer Epidemiologist Kathleen Malone, Ph.D., and colleagues, were published online April 5 in the Journal of Clinical Oncology.
Compared with noncarriers, the breast cancer patients with BRCA1 mutation have a risk 4.5 times higher and those with a BRCA2 mutation have a 3.4 times greater risk of subsequent breast cancer, researchers have found. Carriers of both mutations who were diagnosed with breast cancer before 55 compared to 18 per cent chance of developing cancer is cumulative in the opposite breast within 10 years, compared with a cumulative probability of 5 percent among women who had no mutation.